Integra LifeSciences (NASDAQ:IART) Announces Earnings Results

Integra LifeSciences (NASDAQ:IART) released its quarterly earnings results on Tuesday. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12, Zacks reports. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter in the prior year, the company earned $0.89 earnings per share. The business’s quarterly revenue was up 11.5% compared to the same quarter last year.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $24.04 on Wednesday. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $44.69. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -265.97, a PEG ratio of 0.73 and a beta of 1.17. The company has a 50-day simple moving average of $23.71 and a 200 day simple moving average of $21.83. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Insider Buying and Selling at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on IART shares. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley started coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.